Dr. Stephanie Berg on latest pivotal trials in mCSPC

Stephanie Berg, MD, Dana-Farber Cancer Institute, discusses the results of the of the PEACE-1 and ARASENS trials. In the phase 3 PEACE-1 trial, adding abiraterone acetate (Zytiga) and prednisone to androgen-deprivation therapy (ADT) and docetaxel improved overall survival (OS) and radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer. In the phase 3 ARASENS trial, adding darolutamide to standard ADT and docetaxel boosted OS versus ADT/docetaxel alone in patients with metastatic hormone-sensitive prostate cancer.